More insight on factors causing the inter- and intra-individual variability in tacrolimus concentrations is necessary in order to improve safety of tacrolimus and minimize toxicity directly after heart and lung transplantation.
ID
Bron
Verkorte titel
Aandoening
transplantation
tacrolimus
pharmacokinetics
Ondersteuning
Head of department of National Poisons Information Center
Intensive Care Center of the division of Anesthesiology, Intensive Care and Emergency Medicine, University Medical Center of Utrecht
P.O. Box 85500
3508 GA Utrecht
The Netherlands
Division Anesthesiology, Intensive Care and Emergency Medicine
University Medical Center of Utrecht
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
To show the greater variability of tacrolimus whole blood total and unbound plasma concentrations during the first 6 days post transplantation compared to the variation of tacrolimus concentrations in stable clinical situation.
Achtergrond van het onderzoek
Summary:
Tacrolimus is an immunosuppressive agent used as prophylaxis for organ rejection in lung, heart, liver and kidney transplantation. In previous studies, high inter- and intra-individual variability in tacrolimus blood concentration has been observed among transplant recipients. The range and the factors explaining variation in tacrolimus blood concentrations during the first days post-transplantation in heart and lung transplant recipients are largely unknown. More insight on factors causing the inter- and intra-individual variability in tacrolimus concentrations is necessary in order to adapt dose regimen to individuals. Individualization of dosing regimen is needed to prevent organ toxicity, if tacrolimus concentration is too high, and organ rejection, if tacrolimus concentration is too low or in other words, to improve safety of tacrolimus and minimize toxicity directly after heart and lung transplantation.
Objectives:
Primary objective:
To show that the variability of whole blood total and unbound plasma tacrolimus concentrations during the first 6 days post transplantation is larger than the variation of tacrolimus concentrations in stable clinical situation.
Secondary objectives:
1. To show that unbound tacrolimus plasma concentrations can better predict the occurrence of renal dysfunction than whole blood total tacrolimus concentrations;
2. Identification of variables influencing the unbound tacrolimus plasma concentrations;
3. To evaluate whether variations in tacrolimus concentrations in the first days after lung transplantation in cystic fibrosis patients are higher than without cystic fibrosis.
Long-term objective:
1. The data will be used to develop a kinetic model in the future in order to dose tacrolimus more accurately to prevent adverse effects of tacrolimus.
Design:
We will perform a multiple doses, open-label, observational, prospective and multi-center study in heart and lung transplant recipients.
Population:
Heart and lung transplant recipients admitted to the Intensive Care of a University Medical Center in the first six days post transplantation.
Procedures:
Patients will be included at the outpatient’s department before the transplantation. Tacrolimus will be administered orally twice a day, according to the usual procedure of the Intensive Care Center. Blood and urine will be collected. Presence or absence of cystic fibrosis will be recorded among lung transplant recipients. Concomitant drugs as a cause of kidney dysfunction will be recorded and plasma concentrations will be measured at steady state. Renal function will also be evaluated in a later phase in de outpatient department after circa 1, 3 and 6 months.
Doel van het onderzoek
More insight on factors causing the inter- and intra-individual variability in tacrolimus concentrations is necessary in order to improve safety of tacrolimus and minimize toxicity directly after heart and lung transplantation.
Onderzoeksopzet
Pharmacokinetic parameters will be observed in 30 heart and lung transplant recipients up to the first 6 days after transplantation or shorter if patients are discharged from the intensive care earlier. Renal function will be evaluated in the first days and circa 1, 3 and 6 months after transplantation in the out-patient department.
Onderzoeksproduct en/of interventie
N/A
Publiek
Intensive Care Center of the division of Anesthesiology<br>
Intensive Care and Emergency Medicine<br>
University Medical Center of Utrecht<br>
F06.149<br>
P.O. Box 85500
M.A. Sikma
Utrecht 3508 GA
The Netherlands
+31 (0)88 7555555
m.a.sikma@umcutrecht.nl
Wetenschappelijk
Intensive Care Center of the division of Anesthesiology<br>
Intensive Care and Emergency Medicine<br>
University Medical Center of Utrecht<br>
F06.149<br>
P.O. Box 85500
M.A. Sikma
Utrecht 3508 GA
The Netherlands
+31 (0)88 7555555
m.a.sikma@umcutrecht.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Patients ≥ 18 years;
2. Patients admitted to the ICC of UMCU after heart or lung transplantation;
3. Treated with tacrolimus (Prograft®; Astellas Pharma Europe);
4. Informed consent obtained.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Patients < 18 years;
2. Patients who die within one day after admission to the ICC of UMCU;
3. Withdrawal of informed consent;
4. Allergy towards tacrolimus or macrolides;
5. Patients on total parenteral nutrition.
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL3741 |
NTR-old | NTR3912 |
CCMO | NL40432.041.12 |
ISRCTN | ISRCTN wordt niet meer aangevraagd. |
OMON | NL-OMON39373 |